Literature DB >> 11286653

Issues in HIV/Hepatitis C Co-infection.

Jonathan P. Moorman1.   

Abstract

Co-infection of patients with hepatitis C virus (HCV) and HIV is prevalent. HCV disease is clearly exacerbated in the setting of HIV disease, and the long-term effects of HCV have become an increasing concern as patients live longer on highly active antiretroviral therapy. Although treatment for HCV disease is evolving rapidly, its role in the HIV-infected patient is not well delineated. This review will focus on the major issues in the HIV/HCV co-infected patient and discuss therapy for HCV in the era of highly active antiretroviral therapy.

Entities:  

Year:  2001        PMID: 11286653     DOI: 10.1007/s11908-996-0035-3

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  42 in total

1.  The impact of co-infection with hepatitis C virus and HIV on the tolerability of antiretroviral therapy.

Authors:  D C Melvin; J K Lee; E Belsey; J Arnold; R L Murphy
Journal:  AIDS       Date:  2000-03-10       Impact factor: 4.177

2.  Hepatitis C virus and human immunodeficiency virus: clinical issues in coinfection.

Authors:  D T Dieterich
Journal:  Am J Med       Date:  1999-12-27       Impact factor: 4.965

Review 3.  Hepatitis C virus infection in the United States.

Authors:  M J Alter
Journal:  J Hepatol       Date:  1999       Impact factor: 25.083

4.  Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro.

Authors:  P G Hoggard; S Kewn; M G Barry; S H Khoo; D J Back
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

Review 5.  Activity of combination therapy with interferon alfa-2b plus ribavirin in chronic hepatitis C patients co-infected with HIV.

Authors:  D T Dieterich; J M Purow; R Rajapaksa
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

6.  Does HIV-infection influence the response of chronic hepatitis C to interferon treatment? A French multicenter prospective study. French Multicenter Study Group.

Authors:  X Causse; J L Payen; J Izopet; G Babany; M F Girardin
Journal:  J Hepatol       Date:  2000-06       Impact factor: 25.083

7.  A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group.

Authors:  P Glue; R Rouzier-Panis; C Raffanel; R Sabo; S K Gupta; M Salfi; S Jacobs; R P Clement
Journal:  Hepatology       Date:  2000-09       Impact factor: 17.425

8.  Efficacy and safety of alpha-interferon treatment for chronic hepatitis C in HIV-infected patients. HIV-Hepatitis Spanish Study Group.

Authors:  V Soriano; J García-Samaniego; R Bravo; A Castro; P M Odriozola; J González; M Colmenero; E Carballo; D Suárez; J M Llibre
Journal:  J Infect       Date:  1995-07       Impact factor: 6.072

9.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

10.  Hepatitis C quantification and sequencing in blood products, haemophiliacs, and drug users.

Authors:  P Simmonds; L Q Zhang; H G Watson; S Rebus; E D Ferguson; P Balfe; G H Leadbetter; P L Yap; J F Peutherer; C A Ludlam
Journal:  Lancet       Date:  1990-12-15       Impact factor: 79.321

View more
  1 in total

1.  Update on the Management of Hepatitis C in Liver Transplant Recipients.

Authors:  David A Bobak; Gopal Yadavalli
Journal:  Curr Infect Dis Rep       Date:  2002-04       Impact factor: 3.725

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.